We agree with PwC's conclusion that the model for developing new biotechnology companies needs to change. That's why we will be delivering companies to market over the next four years that are based on innovative research and are investor ready.
This means having a product concept that has been tested and developed, and well as a business model that has been subjected to rigorous scrutiny. This should lead to a lower rate of failure and more investment coming to the Scottish biotechnology sector.
(Dr) Mike Capaldi
Little France Crescent